AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. PYPD
  4. [D] PolyPid Ltd. SEC Filing

[D] PolyPid Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

PolyPid, an Israeli biotechnology company established over five years ago, has filed Form D to report an exempt securities offering under Rule 506(b). The company has successfully completed a $26,692,799 offering, with all securities now sold to 20 investors.

The offering includes equity securities, along with options/warrants and their underlying securities. The company, which currently reports no revenues, maintains its principal operations at 18 Hasivim Street, Petach Tikva, Israel.

Key management includes:

  • Four executive officers: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, and Jonny Missulawin
  • Eight independent directors including Jacob Harel, Yechezkel Barenholz, and others

The offering involves no sales commissions or finder's fees, and none of the proceeds are designated for payments to executives or directors. The offering is not connected to any business combination transaction and is not intended to last more than one year.

PolyPid, un'azienda biotecnologica israeliana fondata oltre cinque anni fa, ha presentato il Modulo D per segnalare un'offerta di titoli esenti ai sensi della Regola 506(b). L'azienda ha completato con successo un'offerta di 26.692.799 $, con tutti i titoli venduti a 20 investitori.

L'offerta comprende titoli azionari, insieme a opzioni/warrant e i relativi titoli sottostanti. L'azienda, che attualmente non registra ricavi, mantiene le sue principali attivit脿 in via Hasivim 18, Petach Tikva, Israele.

Il management chiave include:

  • Quattro dirigenti esecutivi: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky e Jonny Missulawin
  • Otto direttori indipendenti tra cui Jacob Harel, Yechezkel Barenholz e altri

L'offerta non prevede commissioni di vendita n茅 commissioni per intermediari, e nessuno dei proventi 猫 destinato a pagamenti a dirigenti o direttori. L'offerta non 猫 collegata a nessuna operazione di fusione o acquisizione e non 猫 prevista per durare pi霉 di un anno.

PolyPid, una empresa biotecnol贸gica israel铆 establecida hace m谩s de cinco a帽os, ha presentado el Formulario D para reportar una oferta de valores exenta bajo la Regla 506(b). La empresa ha completado exitosamente una oferta de 26.692.799 $, con todos los valores vendidos a 20 inversores.

La oferta incluye valores de capital, junto con opciones/warrants y sus valores subyacentes. La empresa, que actualmente no reporta ingresos, mantiene sus operaciones principales en la calle Hasivim 18, Petach Tikva, Israel.

La gesti贸n clave incluye:

  • Cuatro ejecutivos principales: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky y Jonny Missulawin
  • Ocho directores independientes, incluyendo a Jacob Harel, Yechezkel Barenholz y otros

La oferta no implica comisiones de venta ni pagos a intermediarios, y ninguno de los ingresos est谩 destinado a pagos a ejecutivos o directores. La oferta no est谩 relacionada con ninguna transacci贸n de combinaci贸n empresarial y no est谩 prevista para durar m谩s de un a帽o.

PolyPid電� 5雲� 鞚挫儊 鞝� 靹る霅� 鞚挫姢霛检棙鞚� 靸濍獏瓿淀暀 須岇偓搿�, 506(b) 攴滌箼鞐� 霐半ジ 氅挫牅 歃濌秾 瓿惦毳� 氤搓碃頃橁赴 鞙勴暣 Form D毳� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 齑� 26,692,799 雼煬 攴滊鞚� 瓿惦毳� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, 氇摖 歃濌秾鞚� 20氇呾潣 韴瀽鞛愳棎瓴� 韺愲Г霅橃棃鞀惦媹雼�.

鞚措矆 瓿惦鞐愲姅 欤检嫕 歃濌秾瓿� 鞓奠厴/鞗岆煱韸� 氚� 攴� 旮办磮 歃濌秾鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 順勳灛 毵れ稖鞚� 鞐嗠姅 鞚� 須岇偓電� 鞚挫姢霛检棙 韼橅儉頋� 韹绊伂氚旍潣 頃橃嫓牍� 18氩堨鞐� 氤胳偓毳� 霊愱碃 鞛堨姷雼堧嫟.

欤检殧 瓴届榿歆勳潃 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 4氇呾潣 鞛勳洂: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, Jonny Missulawin
  • 8氇呾潣 霃呺 鞚挫偓, 攴� 欷� Jacob Harel, Yechezkel Barenholz 霌� 韽暔

鞚措矆 瓿惦鞐愲姅 韺愲Г 靾橃垬耄岆倶 欷戧皽 靾橃垬耄岅皜 鞐嗢溂氅�, 靾橃澋旮堨潃 鞛勳洂鞚措倶 鞚挫偓鞐愱矊 歆�旮夒悩歆� 鞎婌姷雼堧嫟. 霕愴暅 鞚措矆 瓿惦電� 靷梾 瓴绊暕 瓯半灅鞕� 甏�霠澊 鞐嗢溂氅� 1雲勳潉 齑堦臣頃橃 鞎婋姅 旮瓣皠 霃欖晥 歆勴枆霅� 鞓堨爼鞛呺媹雼�.

PolyPid, une entreprise biotechnologique isra茅lienne cr茅茅e il y a plus de cinq ans, a d茅pos茅 le formulaire D pour d茅clarer une offre de titres exon茅r茅e conform茅ment 脿 la r猫gle 506(b). La soci茅t茅 a r茅ussi une offre de 26 692 799 $, avec tous les titres vendus 脿 20 investisseurs.

L'offre comprend des titres de participation, ainsi que des options/warrants et leurs titres sous-jacents. La soci茅t茅, qui ne d茅clare actuellement aucun revenu, maintient ses op茅rations principales au 18 rue Hasivim, Petach Tikva, Isra毛l.

Les principaux dirigeants comprennent :

  • Quatre cadres ex茅cutifs : Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky et Jonny Missulawin
  • Huit administrateurs ind茅pendants, dont Jacob Harel, Yechezkel Barenholz, et d'autres

L'offre ne comporte ni commissions de vente ni frais d'interm茅diaire, et aucun produit n'est destin茅 脿 des paiements aux cadres ou administrateurs. L'offre n'est li茅e 脿 aucune transaction de regroupement d'entreprises et n'est pas pr茅vue pour durer plus d'un an.

PolyPid, ein israelisches Biotechnologieunternehmen, das vor 眉ber f眉nf Jahren gegr眉ndet wurde, hat das Formular D eingereicht, um ein von der Regel 506(b) ausgenommenes Wertpapierangebot zu melden. Das Unternehmen hat erfolgreich ein Angebot in H枚he von 26.692.799 $ abgeschlossen, wobei alle Wertpapiere an 20 Investoren verkauft wurden.

Das Angebot umfasst Eigenkapitalwertpapiere sowie Optionen/Warrants und die zugrunde liegenden Wertpapiere. Das Unternehmen, das derzeit keine Ums盲tze meldet, hat seinen Hauptsitz in der Hasivim-Stra脽e 18, Petach Tikva, Israel.

Das Schl眉sselmanagement umfasst:

  • Vier leitende Angestellte: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky und Jonny Missulawin
  • Acht unabh盲ngige Direktoren, darunter Jacob Harel, Yechezkel Barenholz und weitere

Das Angebot beinhaltet keine Verkaufsprovisionen oder Vermittlungsgeb眉hren, und keine der Erl枚se ist f眉r Zahlungen an F眉hrungskr盲fte oder Direktoren vorgesehen. Das Angebot steht in keinem Zusammenhang mit einer Unternehmenszusammenschluss-Transaktion und ist nicht f眉r eine Dauer von mehr als einem Jahr vorgesehen.

Positive
  • PolyPid successfully raised $26.69M through a Rule 506(b) private placement with 20 investors
  • The offering was fully subscribed with $0 remaining to be sold, indicating strong investor interest
Negative
  • Company reports no revenues, indicating pre-revenue development stage status
  • The offering is not intended to last more than one year, suggesting potential need for additional future fundraising

PolyPid, un'azienda biotecnologica israeliana fondata oltre cinque anni fa, ha presentato il Modulo D per segnalare un'offerta di titoli esenti ai sensi della Regola 506(b). L'azienda ha completato con successo un'offerta di 26.692.799 $, con tutti i titoli venduti a 20 investitori.

L'offerta comprende titoli azionari, insieme a opzioni/warrant e i relativi titoli sottostanti. L'azienda, che attualmente non registra ricavi, mantiene le sue principali attivit脿 in via Hasivim 18, Petach Tikva, Israele.

Il management chiave include:

  • Quattro dirigenti esecutivi: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky e Jonny Missulawin
  • Otto direttori indipendenti tra cui Jacob Harel, Yechezkel Barenholz e altri

L'offerta non prevede commissioni di vendita n茅 commissioni per intermediari, e nessuno dei proventi 猫 destinato a pagamenti a dirigenti o direttori. L'offerta non 猫 collegata a nessuna operazione di fusione o acquisizione e non 猫 prevista per durare pi霉 di un anno.

PolyPid, una empresa biotecnol贸gica israel铆 establecida hace m谩s de cinco a帽os, ha presentado el Formulario D para reportar una oferta de valores exenta bajo la Regla 506(b). La empresa ha completado exitosamente una oferta de 26.692.799 $, con todos los valores vendidos a 20 inversores.

La oferta incluye valores de capital, junto con opciones/warrants y sus valores subyacentes. La empresa, que actualmente no reporta ingresos, mantiene sus operaciones principales en la calle Hasivim 18, Petach Tikva, Israel.

La gesti贸n clave incluye:

  • Cuatro ejecutivos principales: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky y Jonny Missulawin
  • Ocho directores independientes, incluyendo a Jacob Harel, Yechezkel Barenholz y otros

La oferta no implica comisiones de venta ni pagos a intermediarios, y ninguno de los ingresos est谩 destinado a pagos a ejecutivos o directores. La oferta no est谩 relacionada con ninguna transacci贸n de combinaci贸n empresarial y no est谩 prevista para durar m谩s de un a帽o.

PolyPid電� 5雲� 鞚挫儊 鞝� 靹る霅� 鞚挫姢霛检棙鞚� 靸濍獏瓿淀暀 須岇偓搿�, 506(b) 攴滌箼鞐� 霐半ジ 氅挫牅 歃濌秾 瓿惦毳� 氤搓碃頃橁赴 鞙勴暣 Form D毳� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 齑� 26,692,799 雼煬 攴滊鞚� 瓿惦毳� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, 氇摖 歃濌秾鞚� 20氇呾潣 韴瀽鞛愳棎瓴� 韺愲Г霅橃棃鞀惦媹雼�.

鞚措矆 瓿惦鞐愲姅 欤检嫕 歃濌秾瓿� 鞓奠厴/鞗岆煱韸� 氚� 攴� 旮办磮 歃濌秾鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 順勳灛 毵れ稖鞚� 鞐嗠姅 鞚� 須岇偓電� 鞚挫姢霛检棙 韼橅儉頋� 韹绊伂氚旍潣 頃橃嫓牍� 18氩堨鞐� 氤胳偓毳� 霊愱碃 鞛堨姷雼堧嫟.

欤检殧 瓴届榿歆勳潃 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 4氇呾潣 鞛勳洂: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, Jonny Missulawin
  • 8氇呾潣 霃呺 鞚挫偓, 攴� 欷� Jacob Harel, Yechezkel Barenholz 霌� 韽暔

鞚措矆 瓿惦鞐愲姅 韺愲Г 靾橃垬耄岆倶 欷戧皽 靾橃垬耄岅皜 鞐嗢溂氅�, 靾橃澋旮堨潃 鞛勳洂鞚措倶 鞚挫偓鞐愱矊 歆�旮夒悩歆� 鞎婌姷雼堧嫟. 霕愴暅 鞚措矆 瓿惦電� 靷梾 瓴绊暕 瓯半灅鞕� 甏�霠澊 鞐嗢溂氅� 1雲勳潉 齑堦臣頃橃 鞎婋姅 旮瓣皠 霃欖晥 歆勴枆霅� 鞓堨爼鞛呺媹雼�.

PolyPid, une entreprise biotechnologique isra茅lienne cr茅茅e il y a plus de cinq ans, a d茅pos茅 le formulaire D pour d茅clarer une offre de titres exon茅r茅e conform茅ment 脿 la r猫gle 506(b). La soci茅t茅 a r茅ussi une offre de 26 692 799 $, avec tous les titres vendus 脿 20 investisseurs.

L'offre comprend des titres de participation, ainsi que des options/warrants et leurs titres sous-jacents. La soci茅t茅, qui ne d茅clare actuellement aucun revenu, maintient ses op茅rations principales au 18 rue Hasivim, Petach Tikva, Isra毛l.

Les principaux dirigeants comprennent :

  • Quatre cadres ex茅cutifs : Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky et Jonny Missulawin
  • Huit administrateurs ind茅pendants, dont Jacob Harel, Yechezkel Barenholz, et d'autres

L'offre ne comporte ni commissions de vente ni frais d'interm茅diaire, et aucun produit n'est destin茅 脿 des paiements aux cadres ou administrateurs. L'offre n'est li茅e 脿 aucune transaction de regroupement d'entreprises et n'est pas pr茅vue pour durer plus d'un an.

PolyPid, ein israelisches Biotechnologieunternehmen, das vor 眉ber f眉nf Jahren gegr眉ndet wurde, hat das Formular D eingereicht, um ein von der Regel 506(b) ausgenommenes Wertpapierangebot zu melden. Das Unternehmen hat erfolgreich ein Angebot in H枚he von 26.692.799 $ abgeschlossen, wobei alle Wertpapiere an 20 Investoren verkauft wurden.

Das Angebot umfasst Eigenkapitalwertpapiere sowie Optionen/Warrants und die zugrunde liegenden Wertpapiere. Das Unternehmen, das derzeit keine Ums盲tze meldet, hat seinen Hauptsitz in der Hasivim-Stra脽e 18, Petach Tikva, Israel.

Das Schl眉sselmanagement umfasst:

  • Vier leitende Angestellte: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky und Jonny Missulawin
  • Acht unabh盲ngige Direktoren, darunter Jacob Harel, Yechezkel Barenholz und weitere

Das Angebot beinhaltet keine Verkaufsprovisionen oder Vermittlungsgeb眉hren, und keine der Erl枚se ist f眉r Zahlungen an F眉hrungskr盲fte oder Direktoren vorgesehen. Das Angebot steht in keinem Zusammenhang mit einer Unternehmenszusammenschluss-Transaktion und ist nicht f眉r eine Dauer von mehr als einem Jahr vorgesehen.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities
OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
X None
Entity Type
0001611842
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
PolyPid Ltd.
Jurisdiction of Incorporation/Organization
ISRAEL
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
PolyPid Ltd.
Street Address 1 Street Address 2
18 HASIVIM STREET
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
PETACH TIKVA ISRAEL 495376 +972-74-719-5700

3. Related Persons

Last Name First Name Middle Name
Czaczkes Akselbrad Dikla
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Hazan Dalit
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Warshavsky Ori
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Missulawin Jonny
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Harel Jacob
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Barenholz Yechezkel
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Dror Nir
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
BenAmram Yossi
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Krinsky Itzhak
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Stein Robert B.
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Tweezer-Zaks Nurit
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Jacobovitz Yitzchak
Street Address 1 Street Address 2
18 Hasivim Street
City State/Province/Country ZIP/PostalCode
Petach Tikva ISRAEL 495376
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
X Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
AG真人官方 Estate
Commercial
Construction
REITS & Finance
Residential
Other AG真人官方 Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
X No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-06-16 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number X None
NONE None
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
NONE
City State/Province/Country ZIP/Postal Code
NONE Unknown 00000
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
Foreign/non-US
CALIFORNIA
MARYLAND
NEW YORK
TEXAS

13. Offering and Sales Amounts

Total Offering Amount $26,692,799 USD
or Indefinite
Total Amount Sold $26,692,799 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

 Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
20

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $0 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
PolyPid Ltd. /s/ Jonny Missulawin Jonny Missulawin Chief Financial Officer 2025-06-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

Source:

FAQ

What type of securities offering did PYPD file on June 28, 2025?

PYPD filed a Form D for an exempt securities offering under Rule 506(b) of Regulation D. The offering included equity securities, options/warrants, and securities to be acquired upon exercise of those rights.

How much did PYPD raise in their June 2025 private placement?

PYPD raised $26,692,799 in total proceeds from the offering, with the entire amount being sold to investors, leaving $0 remaining to be sold.

How many investors participated in PYPD's June 2025 private placement?

According to the Form D filing, a total of 20 investors participated in PYPD's private placement offering.

What is PYPD's current revenue status as disclosed in the Form D?

PYPD indicated in the Form D that it currently has 'No Revenues' in its revenue range disclosure.

In which states did PYPD offer these securities?

PYPD offered the securities in four U.S. states: California, Maryland, New York, and Texas.
Stock PYPD logo
Polypid Ltd.

NASDAQ:PYPD

PYPD Rankings

#5163 Ranked by Market Cap
N/A Ranked by Dividends

PYPD Latest News

Aug 13, 2025
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Aug 12, 2025
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Jul 30, 2025
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
Jul 15, 2025
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
Jun 16, 2025
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PYPD Latest SEC Filings

Aug 13, 2025
[6-K] PolyPid Ltd. Current Report (Foreign Issuer)
Aug 13, 2025
[S-8] PolyPid Ltd. Employee Benefit Plan Registration
Aug 13, 2025
[SCHEDULE 13G/A] PolyPid Ltd. SEC Filing
Aug 13, 2025
[6-K] PolyPid Ltd. Current Report (Foreign Issuer)
Aug 12, 2025
[6-K] PolyPid Ltd. Current Report (Foreign Issuer)

PYPD Stock Data

55.48M
7.11M
25.65%
49.04%
0.64%
Biotechnology
Healthcare
Israel
Petah Tikva